广西医学
廣西醫學
엄서의학
Guangxi Medical Journal
2015年
9期
1240-1242,1261
,共4页
王丽%李云双%陈永升%聂伟业%尹晓林
王麗%李雲雙%陳永升%聶偉業%尹曉林
왕려%리운쌍%진영승%섭위업%윤효림
非霍奇金淋巴瘤%异基因%造血干细胞输注%化疗%老年人%微移植
非霍奇金淋巴瘤%異基因%造血榦細胞輸註%化療%老年人%微移植
비곽기금림파류%이기인%조혈간세포수주%화료%노년인%미이식
Non-Hodgkins lymphoma%Allogene%Hematopoietic stem cell transfusion%Chemotherapy%Elderly%Microtransplantation
目的:观察异基因造血干细胞分次输注(微移植)支持下联合化疗治疗老年非霍奇金淋巴瘤( NHL )的临床疗效。方法 NHL老年患者3例,年龄70~78岁,其中病例1为反复治疗后复发患者,病例2和病例3均为初治患者,分别予CHOP(环磷酰胺+阿霉素+长春新碱+强的松)方案或GeMoD(吉西他滨+奥沙利铂+地塞米松)方案化疗。供者为人类白细胞抗原半相合的患者子女,采集重组人粒细胞集落刺激因子动员后的供者外周血干细胞,于化疗结束后约36 h分次输注。观察患者的疾病状态、生存时间、骨髓抑制情况及不良反应等。结果病例1、病例2、病例3治疗后分别达病情稳定、完全缓解和部分缓解,生存期分别为4个月、26个月、10个月。病例1在化疗第3、第4疗程出现粒细胞缺乏,在第4疗程出现严重血小板减少,其余患者未出现严重的骨髓抑制,所有患者均未输注血小板。所有患者未出现移植物抗宿主病。结论化疗联合微移植治疗老年淋巴瘤骨髓抑制轻,使用安全,值得更大规模的临床研究进行探索。
目的:觀察異基因造血榦細胞分次輸註(微移植)支持下聯閤化療治療老年非霍奇金淋巴瘤( NHL )的臨床療效。方法 NHL老年患者3例,年齡70~78歲,其中病例1為反複治療後複髮患者,病例2和病例3均為初治患者,分彆予CHOP(環燐酰胺+阿黴素+長春新堿+彊的鬆)方案或GeMoD(吉西他濱+奧沙利鉑+地塞米鬆)方案化療。供者為人類白細胞抗原半相閤的患者子女,採集重組人粒細胞集落刺激因子動員後的供者外週血榦細胞,于化療結束後約36 h分次輸註。觀察患者的疾病狀態、生存時間、骨髓抑製情況及不良反應等。結果病例1、病例2、病例3治療後分彆達病情穩定、完全緩解和部分緩解,生存期分彆為4箇月、26箇月、10箇月。病例1在化療第3、第4療程齣現粒細胞缺乏,在第4療程齣現嚴重血小闆減少,其餘患者未齣現嚴重的骨髓抑製,所有患者均未輸註血小闆。所有患者未齣現移植物抗宿主病。結論化療聯閤微移植治療老年淋巴瘤骨髓抑製輕,使用安全,值得更大規模的臨床研究進行探索。
목적:관찰이기인조혈간세포분차수주(미이식)지지하연합화료치료노년비곽기금림파류( NHL )적림상료효。방법 NHL노년환자3례,년령70~78세,기중병례1위반복치료후복발환자,병례2화병례3균위초치환자,분별여CHOP(배린선알+아매소+장춘신감+강적송)방안혹GeMoD(길서타빈+오사리박+지새미송)방안화료。공자위인류백세포항원반상합적환자자녀,채집중조인립세포집락자격인자동원후적공자외주혈간세포,우화료결속후약36 h분차수주。관찰환자적질병상태、생존시간、골수억제정황급불량반응등。결과병례1、병례2、병례3치료후분별체병정은정、완전완해화부분완해,생존기분별위4개월、26개월、10개월。병례1재화료제3、제4료정출현립세포결핍,재제4료정출현엄중혈소판감소,기여환자미출현엄중적골수억제,소유환자균미수주혈소판。소유환자미출현이식물항숙주병。결론화료연합미이식치료노년림파류골수억제경,사용안전,치득경대규모적림상연구진행탐색。
Objective To investigate the clinic efficacy of combined chemotherapy supported by allogeneic hematopoietic stem cell transfusion(microtransplantation) for elderly patients with non-Hodgkins lymphoma(NHL).Methods Three elderly patients with NHL aged from 70 to 78 years were enrolled in the study .The patient in Case 1 relapsed after multiple chemotherapy .The patents in Case 2 and Case 3 were newly diagnosed as NHL ,and were treated with chemotherapy regimen of CHOP ( cyclophosphamide +doxorubicin+vincristine+prednisone ) or GeMod( gemcitabine+oxaliplatin+dexamethasone ) .The donors were children of patients with human leukocyte antigen semi-matched.Peripheral blood stem cells ( PBSC) from the donors were mobilized with granulocyte colony-stimulating factor and then were collected.Patients were transfused with PBSC 36 hours after the chemotherapy finished .The disease status,survival time,myelosuppression and side effects were observed .Results The disease statuses after treatment of Case 1,Case 2 and Case 3 were stable disease,complete response and partial response ,respectively.The survival time of Case 1,Case 2 and Case 3 was 4 months,26 months and 10 months, respectively .Granulocytopenia was observed in Case 1 during the third and forth period of chemotherapy ,and severe thrombocytopenia only occurred in Case 1 during the forth period.Severe myelosuppression did not occurred in other cases .None of three cases received transfusion of platelet .Graft versus host disease was not found in any patients .Conclusion Chemotherapy combined with microtransplantation has mild myelosuppression ,and was safe for elderly patients with NHL .Large-scale clinic study for further research is deserved .